These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30843643)

  • 1. Patients' reactions and follow-up testing decisions related to Tay-Sachs (HEXA) variants of uncertain significance results.
    Yip T; Grinzaid KA; Bellcross C; Moore RH; Page PZ; Hardy MW
    J Genet Couns; 2019 Aug; 28(4):738-749. PubMed ID: 30843643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for Tay-Sachs disease carriers by full-exon sequencing with novel variant interpretation outperforms enzyme testing in a pan-ethnic cohort.
    Cecchi AC; Vengoechea ES; Kaseniit KE; Hardy MW; Kiger LA; Mehta N; Haque IS; Moyer K; Page PZ; Muzzey D; Grinzaid KA
    Mol Genet Genomic Med; 2019 Aug; 7(8):e836. PubMed ID: 31293106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tay-Sachs Disease: Two Novel Rare HEXA Mutations from Pakistan and Morocco.
    Bibi F; Ullah A; Bourinaris T; Efthymiou S; Kriouile Y; Sultan T; Haider S; Salpietro V; Houlden H; Kaukab Raja G
    Klin Padiatr; 2021 Sep; 233(5):226-230. PubMed ID: 33831955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of gene patents and licensing practices on access to genetic testing and carrier screening for Tay-Sachs and Canavan disease.
    Colaianni A; Chandrasekharan S; Cook-Deegan R
    Genet Med; 2010 Apr; 12(4 Suppl):S5-S14. PubMed ID: 20393311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Modern Dilemma: How Experts Grapple with Ambiguous Genetic Test Results.
    Scherr CL; Ross Arguedas AA; Getachew-Smith H; Marshall-Fricker C; Shrestha N; Brooks K; Fischhoff B; Vadaparampil ST
    Med Decis Making; 2020 Jul; 40(5):655-668. PubMed ID: 32734842
    [No Abstract]   [Full Text] [Related]  

  • 6. Prenatal Diagnosis of Tay-Sachs Disease.
    Zhang J; Chen H; Kornreich R; Yu C
    Methods Mol Biol; 2019; 1885():233-250. PubMed ID: 30506202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic counselors' practices and confidence regarding variant of uncertain significance results and reclassification from BRCA testing.
    Scherr CL; Lindor NM; Malo TL; Couch FJ; Vadaparampil ST
    Clin Genet; 2015 Dec; 88(6):523-9. PubMed ID: 25640009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving accuracy of Tay Sachs carrier screening of the non-Jewish population: analysis of 34 carriers and six late-onset patients with HEXA enzyme and DNA sequence analysis.
    Park NJ; Morgan C; Sharma R; Li Y; Lobo RM; Redman JB; Salazar D; Sun W; Neidich JA; Strom CM
    Pediatr Res; 2010 Feb; 67(2):217-20. PubMed ID: 19858779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tay-Sachs disease carrier screening: a model for prevention of genetic disease.
    Kaplan F
    Genet Test; 1998; 2(4):271-92. PubMed ID: 10464605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer patients' experience of receiving variant of uncertain significance results: An Asian perspective.
    Ishak ND; Shaw T; Li ST; Yuen J; Goh HX; Chua ZY; Suresh P; Que FVF; Zhang Z; Chiang J; Ngeow J
    J Genet Couns; 2024 Oct; 33(5):985-994. PubMed ID: 37864575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GM2 gangliosidoses in Spain: analysis of the HEXA and HEXB genes in 34 Tay-Sachs and 14 Sandhoff patients.
    Gort L; de Olano N; Macías-Vidal J; Coll MA;
    Gene; 2012 Sep; 506(1):25-30. PubMed ID: 22789865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tay-Sachs disease: a novel mutation from India.
    Khera D; John J; Singh K; Faruq M
    BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-based genetic screening for reproductive counseling: the Tay-Sachs disease model.
    Kaback MM
    Eur J Pediatr; 2000 Dec; 159 Suppl 3():S192-5. PubMed ID: 11216898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tay-Sachs disease screening and counseling families at risk for metabolic disease.
    Sutton VR
    Obstet Gynecol Clin North Am; 2002 Jun; 29(2):287-96. PubMed ID: 12108829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prenatal genetic carrier testing using triple disease screening.
    Eng CM; Schechter C; Robinowitz J; Fulop G; Burgert T; Levy B; Zinberg R; Desnick RJ
    JAMA; 1997 Oct; 278(15):1268-72. PubMed ID: 9333269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health behaviors among unaffected participants following receipt of variants of uncertain significance in cardiomyopathy-associated genes.
    Miller IM; Lewis KL; Lawal TA; Ng D; Johnston JJ; Biesecker BB; Biesecker LG
    Genet Med; 2019 Mar; 21(3):748-752. PubMed ID: 29997389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid and cost-effective method for the detection of the c.533G>A mutation in the HEXA gene.
    Ribeiro D; Duarte AJ; Amaral O
    Genet Test Mol Biomarkers; 2011 Mar; 15(3):123-6. PubMed ID: 21204700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carrier screening for cystic fibrosis, Gaucher disease, and Tay-Sachs disease in the Ashkenazi Jewish population: the first 1000 cases at New York University Medical Center, New York, NY.
    Kronn D; Jansen V; Ostrer H
    Arch Intern Med; 1998 Apr; 158(7):777-81. PubMed ID: 9554684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding variants of uncertain significance in the era of multigene panels: Through the eyes of the patient.
    Reuter C; Chun N; Pariani M; Hanson-Kahn A
    J Genet Couns; 2019 Aug; 28(4):878-886. PubMed ID: 31050105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tay-Sachs disease carrier screening: a 21-year experience.
    D'Souza G; McCann CL; Hedrick J; Fairley C; Nagel HL; Kushner JD; Kessel R
    Genet Test; 2000; 4(3):257-63. PubMed ID: 11142756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.